Tocilizumab for the Treatment of Mevalonate Kinase Deficiency
Mevalonate kinase deficiency (MKD) is a severe autoinflammatory disease caused by recessive mutations in MVK resulting in reduced function of the enzyme mevalonate kinase, involved in the cholesterol/isoprenoid pathway. MKD presents with periodic episodes of severe systemic inflammation, poor qualit...
Saved in:
Main Authors: | Nadia K. Rafiq (Author), Helen Lachmann (Author), Frodi Joensen (Author), Troels Herlin (Author), Paul A. Brogan (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2018-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vasculitis in a patient with mevalonate kinase deficiency (MKD): a case report
by: Ebun Omoyinmi, et al.
Published: (2021) -
Interleukin-1 antagonists in Mevalonate Kinase Deficiency
by: Hachulla E, et al.
Published: (2011) -
Tocilizumab for treating mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: a case series and literature review
by: Yandie Li, et al.
Published: (2024) -
Efficacy of Anakinra Treatment in two Moroccan Patients With Mevalonate Kinase Deficiency
by: Manal Souali, et al.
Published: (2023) -
A case of neonatal sweet syndrome associated with mevalonate kinase deficiency
by: Margaret Irwin, et al.
Published: (2023)